1 |
Boyd RA, Stern RH, Stewart BH, et al., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8.
DOI
ScienceOn
|
2 |
Hong SP, Chang KS, Choi DH, et al., Effect od Atorvastatin on the Pharmacokinetics of Diltiazem and Its main metabolite, Desacetyldiltiazem, in rats. Arch Pharm Res 2007; 30; 90-95.
과학기술학회마을
DOI
|
3 |
Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 1983; 16: 203-9.
DOI
ScienceOn
|
4 |
Sorkin E M, Clissold SP, Brogden RN. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 182-7.
DOI
ScienceOn
|
5 |
Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-90.
DOI
ScienceOn
|
6 |
Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 1999; 16: 225-31.
DOI
ScienceOn
|
7 |
Choi BC, Choi JS. Pharmacokinetic interaction between simvastatin and nicardipine. Kor J Clin Pharm 2009; 19: 32-36.
과학기술학회마을
|
8 |
Choi DH, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Durg Metabol 2009; 34: 163- 168.
DOI
ScienceOn
|
9 |
Grundy JS, Kherani R, Foster RT. Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B Biomed Appl 1994; 654: 146-52.
DOI
ScienceOn
|
10 |
Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-90.
DOI
ScienceOn
|
11 |
Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174-80.
|
12 |
Hokama N, Hobara N, Sakai M, et al., Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol 2002; 54: 821-26.
DOI
ScienceOn
|
13 |
Ford JM. Modulators of multidrug resistance preclinical studies. Hematol Oncol Clin N Am 1995; 9: 337-42.
|
14 |
Fruehauf JP, Manetta A. Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib Gynecol Obstet 1994; 19: 39-45.
|
15 |
Endo T, Kimura O, Sakata M. Effects of P-glycoprotein inhibitors on cadmium accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Toxicol Appl Pharmacol 2002; 185: 166-72.
DOI
ScienceOn
|
16 |
Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53: 828-47.
DOI
ScienceOn
|
17 |
Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet 2003; 42: 1141-60.
DOI
ScienceOn
|
18 |
Wu X, Whitheld LR, Stewart, BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-15.
DOI
ScienceOn
|
19 |
Holtzman CW, Wiggins BS, Spinler SA. Role of Pglycoprotein in Statin Drug Interactions. Pharmacotherapy 2006; 26: 1601-07.
DOI
ScienceOn
|
20 |
Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-74.
DOI
ScienceOn
|
21 |
Choi DH, Chang KS, Hong SP, et al., Effect of Atorvastatin on the Intravenous and Oral Pharmacokinetics of Verapamil in Rat. Biopharm Drug Dispos 2008; 29: 45- 50.
DOI
ScienceOn
|
22 |
Watkins PB, Wrighton SA, Schuetz EG, et al., Identification of glucocorticoid-inducible cytochromes P- 450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-35.
DOI
|
23 |
Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980; 46: 1047-53.
DOI
ScienceOn
|
24 |
Guengerich FP, Brian WR, Iwasaki M. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4, J Med Chem 1991; 4: 1838-44.
|
25 |
Iribarne C, Dréano LG, Bardou JF, Ménez G, et al., Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997; 117: 13-9.
DOI
ScienceOn
|
26 |
Kolars JC, Schmiedlin-Ren P, Dobbins 3rd WO, et al., Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 1992; 102: 1186-92.
|
27 |
Gan SL, Moseley MA, Khosla B, et al., CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 1996; 24: 344-50.
|
28 |
Watkins PB. The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv Drug Deliv Rev 1996; 27: 161-7.
|
29 |
Wacher VH, Silverman JA, Zhang Y, et al., Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-8.
DOI
|
30 |
Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm Res 1999; 16: 225-31.
DOI
ScienceOn
|
31 |
Chaudhary PM, Robinson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-90.
DOI
ScienceOn
|
32 |
Raemsch KD, Sommer JC. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5: 18-24.
|
33 |
Van Asperen J, Van Tellingen O, Sparreboom A, et al., Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker. Br J Cancer 1997; 76: 1181-87.
DOI
ScienceOn
|
34 |
Walter DG, Gruchy BS, Renwick AG, et al., The first pass metabolism of nifedipine in man. Br J Clin Pharmacol 1984; 18: 951-6.
DOI
ScienceOn
|